Actinium Pharmaceuticals (NYSE:ATNM) Upgraded by StockNews.com to “Hold” Rating

StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSE:ATNM) from a sell rating to a hold rating in a research report released on Friday morning.

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Actinium Pharmaceuticals in a research note on Tuesday, April 1st. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $7.40.

Actinium Pharmaceuticals Stock Performance

ATNM stock opened at $1.21 on Friday. The company has a 50 day moving average price of $1.28 and a two-hundred day moving average price of $1.39. The stock has a market capitalization of $37.75 million, a P/E ratio of -0.87 and a beta of -0.27. Actinium Pharmaceuticals has a one year low of $1.03 and a one year high of $10.24.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ATNM. Squarepoint Ops LLC grew its position in Actinium Pharmaceuticals by 25.4% during the fourth quarter. Squarepoint Ops LLC now owns 183,262 shares of the company’s stock valued at $231,000 after acquiring an additional 37,159 shares during the period. Nuveen Asset Management LLC grew its holdings in shares of Actinium Pharmaceuticals by 49.5% during the 4th quarter. Nuveen Asset Management LLC now owns 148,560 shares of the company’s stock worth $187,000 after purchasing an additional 49,214 shares during the period. Deutsche Bank AG raised its holdings in Actinium Pharmaceuticals by 413.6% in the fourth quarter. Deutsche Bank AG now owns 123,134 shares of the company’s stock valued at $155,000 after buying an additional 99,158 shares during the period. Bank of America Corp DE raised its holdings in Actinium Pharmaceuticals by 76.6% in the fourth quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock valued at $99,000 after buying an additional 34,176 shares during the period. Finally, Northern Trust Corp lifted its position in Actinium Pharmaceuticals by 4.9% during the fourth quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock valued at $317,000 after buying an additional 11,812 shares in the last quarter. 27.50% of the stock is owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).